'Siemens is excited to not only receive clearance for 21 allergens, but to be the first company to begin offering eight new molecular allergy tests to laboratories and clinicians throughout the United States as part of this release,” said Dave Hickey, CEO, Chemistry, Immunoassay, Automation, and Diagnostics IT Business Unit, Siemens Healthcare Diagnostics. 

Specifically, the eight new molecular allergens available from Siemens for use on the IMMULITE System 2000/XPi include tests for major allergenic proteins derived from cat dander, dog dander, house dust mites, Aspergillus (mold), and shrimp 

*IMMULITE 2000 XPi is not available for sale in the United States 

The Siemens Healthcare Sector is one of the world’s largest suppliers to the healthcare industry and a trendsetter in medical imaging, laboratory diagnostics, medical information technology and hearing aids. Siemens offers its customers products and solutions for the entire range of patient care from a single source – from prevention and early detection to diagnosis, and on to treatment and aftercare. By optimizing clinical workflows for the most common diseases, Siemens also makes healthcare faster, better and more cost-effective. Siemens Healthcare employs some 48,000 employees worldwide and operates around the world. In fiscal year 2010 (to September 30), the Sector posted revenue of 12.4 billion euros and profit of around 750 million euros. For further information please visit: www.siemens.com/healthcare